Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped FDA asked to administratively split from IND115621- to open a new IND you need to file a protocol we only drafted it to get the IND open - never initiated

Conditions

Triple-negative Breast Cancer

Interventions

DRUG: IMMU-132 infusion is administered to participants in one arm for the study
DRUG: IMMU-132 plus Carboplatin infusion

Sponsor

Gilead Sciences